We are live on ! Find out more
OBIO icon

Orchestra BioMed
OBIO

62 hedge funds and large institutions have $140M invested in Orchestra BioMed in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 5 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

220% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 5

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

80% more first-time investments, than exits

New positions opened: 9 | Existing positions closed: 5

5% more funds holding

Funds holding: 59 → 62 (+3)

1.05% more ownership

Funds ownership: 68.8% → 69.84% (+1%)

2% more capital invested

Capital invested by funds: $138M → $140M (+$2.31M)

Holders
62
Holders Change
+3
Holders Change %
+5.08%
% of All Funds
1.04%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
9
Increased
16
Reduced
5
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Hudson Bay Capital Management
Hudson Bay Capital Management
Connecticut
+$2.74M
2
Millennium Management
Millennium Management
New York
+$1.94M
3
WRBC
W.R. Berkley Corp
Connecticut
+$1.82M
4
KPF
K2 Principal Fund
Ontario, Canada
+$1.74M
5
LSC
Logan Stone Capital
Illinois
+$1.64M

Top Sellers

Rank Fund Capital Flow
1
DKCM
Davidson Kempner Capital Management
New York
-$4.97M
2
PA
Perceptive Advisors
New York
-$4.46M
3
AAA
Affinity Asset Advisors
New York
-$2.97M
4
SCM
Shaolin Capital Management
Florida
-$1.98M
5
M
Murchinson
Ontario, Canada
-$992K
Name Holding Trade Value Shares
Change 		Change in
Stake
KKRC
26
Kohlberg Kravis Roberts & Co
New York
$2.48M -$169 -17 -0%
ASM
27
ATW SPAC Management
New York
$1.91M – – –
KPF
28
K2 Principal Fund
Ontario, Canada
$1.74M +$1.74M +175,000 New
KIM
29
Karpus Investment Management
New York
$1.6M – – –
LP
30
LMR Partners
United Kingdom
$1.45M – – –
PVI
31
Pura Vida Investments
New York
$1.04M – – –
CM
32
Cohanzick Management
New York
$1.03M +$933K +93,824 +938%
SIM
33
Sandia Investment Management
Massachusetts
$1.01M +$1.01M +101,769 New
CIM
34
Cowen Investment Management
New York
$996K – – –
RA
35
RiverPark Advisors
New York
$996K +$994K +100,000 New
Goldman Sachs
36
Goldman Sachs
New York
$937K +$355K +35,700 +61%
Marshall Wace
37
Marshall Wace
United Kingdom
$801K – – –
PMAM
38
Picton Mahoney Asset Management
Ontario, Canada
$781K – – –
HI
39
HBK Investments
Texas
$690K +$76.6K +7,704 +13%
MC
40
Meteora Capital
Florida
$603K +$602K +60,572 New
EC
41
Elequin Capital
New York
$498K +$497K +50,000 New
HF
42
HRT Financial
New York
$496K -$994 -100 -0.2%
TD Asset Management
43
TD Asset Management
Ontario, Canada
$462K – – –
KL
44
KIM LLC
Kansas
$462K +$461K +46,394 New
AI
45
Arena Investors
New York
$434K – – –
SSA
46
Schonfeld Strategic Advisors
New York
$428K +$427K +42,998 New
Alyeska Investment Group
47
Alyeska Investment Group
Illinois
$249K – – –
Nomura Holdings
48
Nomura Holdings
Japan
$205K – – –
CCM
49
CAAS Capital Management
New York
$202K – – –
SC
50
Sagefield Capital
Texas
$182K – – –
1
2
3

OBIO Hedge Fund Activity: Q2 2022 in Review

62 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q2 2022, worth a combined $140M — up 1.7% from $138M a quarter earlier.

Buyers outnumbered sellers: 9 funds opened new OBIO positions and 5 closed out — a net gain of 4 holders — while 16 added to existing stakes and 5 trimmed.

The largest buyer was Hudson Bay Capital Management, opening a new position worth an estimated $2.74M. The largest seller was Davidson Kempner Capital Management, cutting an estimated $4.97M.

  • 62 institutional investors held Orchestra BioMed (OBIO) as of Q2 2022, up from 59 in Q1 2022.
  • Funds reported $140M of Orchestra BioMed stock for Q2 2022, up 1.7% quarter-over-quarter.
  • 9 funds opened new Orchestra BioMed positions in Q2 2022 and 5 closed out, a net change of +4 holders.
  • The largest Orchestra BioMed buyer in Q2 2022 was Hudson Bay Capital Management, an estimated $2.74M added.
  • The largest Orchestra BioMed seller in Q2 2022 was Davidson Kempner Capital Management, an estimated $4.97M sold.

Based on aggregated 13F filings for Q2 2022.